Juvelook and RE2O: what actually separates them

Juvelook leaves PDLLA particles in the dermis so that collagen forms around them — a stimulatory product. RE2O injects extracellular matrix derived from donated human skin — a replacement product. Same syringe, opposite jobs.

On evidence they split like this. We could not find a clinical trial naming Juvelook. What exists is class-level PDLLA data, and the largest of those studies used a different product. RE2O does have one trial naming the product, but it sits in a legal category that never required one — as human tissue it needs no pre-market clinical data, carries no per-product approval number, and is monitored through a coarser adverse-event route than a medical device.

Put plainly: Juvelook is thin on product-specific evidence; RE2O is thin on regulatory scaffolding. Neither is a finished, fully tested product. The empty space is simply in a different place. Nothing below says one is better than the other, because no study has compared them.

We could not find a clinical trial naming Juvelook. What gets cited in consultation is either class-level PDLLA data or, more often, a trial of a different product entirely. That distinction matters, so here it is study by study.

• Ting W et al. 2024 (Aesthet Surg J 2024;44(12):NP898–NP905) — randomised, evaluator-blinded, multicentre, 260 subjects, nasolabial folds. The largest PDLLA trial there is. But the product is AestheFill, not Juvelook, and the design is a non-inferiority trial, so the stated conclusion is “noninferior to hyaluronic acid.” The one significant comparison reported is at 24 weeks (67.6% versus 60.9% achieving at least one grade of improvement, p<0.05).
• Seo SB et al. 2026 (Aesthetic Plast Surg 2026;50(9):3382–3388) — 40 subjects, no control group; measures kept rising to 24 weeks. But this was five sessions delivered by a needle-free microjet device, which cannot be set beside Ting's single injection.
• Park JY et al. 2026 (Skin Res Technol 2026;32(1):e70324) — PDLLA versus PLLA, 33 subjects, split-face. Improvement was comparable between the two. Another non-inferiority conclusion.

So every human dataset in this class reaches “not worse than hyaluronic acid or PLLA,” and the largest of them is another company's product. If “clinically proven” comes up in a consultation, the question worth asking is whether that trial used Juvelook at all.

RE2O does have a human trial naming the product: 20 subjects over 20 weeks, split-face, double-blind, randomised, against hyaluronic acid alone (Int J Mol Sci 2026;27(5):2193 / NCT07155278). Few boosters have a design that tight.

Read alongside it, though:

• The trial was run after launch (November 2024). It is not a trial the product had to pass to reach the market.
• It was also registered retrospectively, in September 2025, four months after completion.
• The authors themselves write that with 20 subjects across many endpoints and timepoints there is a risk of inflated type I error, that no adjustment for multiplicity was made, and that some significant findings should be interpreted with caution.
• The test arm was not hADM alone but hADM combined with hyaluronic acid, against hyaluronic acid alone.
• For human tissue, approval is granted to the tissue bank, not to the product. A per-product approval number does not exist in the first place.
• Adverse-event reporting is coarser than for a medical device. Under the tissue act, serious events are reported within 7 days and general events annually — not the granular device reporting regime. In July 2026 the MFDS pre-announced an amendment to the tissue-safety rules that would tighten general adverse-event reporting for ECM skin boosters to twice a year.

What this side does have is tighter traceability of the raw material — donor through distribution. Different things are guaranteed, not more or fewer.

Juvelook: hyaluronidase dissolves hyaluronic acid, and PDLLA particles are not dissolved by it. A paper on managing PDLLA nodules states that, unlike hyaluronic acid nodules, PDLLA nodules do not respond to enzymatic treatment (J Cosmet Dermatol 2025;24(4):e70158). Note that this is a two-author opinion piece whose authors declare ties to a manufacturer.

One vascular event is reported at class level: a 23-year-old woman developed multiple branch retinal artery occlusions after PDLLA injection at the glabella (BMC Ophthalmol 2023;23(1):86). How to read it: the product was AestheFill, not Juvelook, and after treatment her best-corrected visual acuity recovered from hand motion at 30 cm to 0.3 within two months. It is a single case, so it carries no incidence.

RE2O: said to resorb gradually, but we could not find a primary study of any agent that reverses it.

So if the priority is starting with something that can be undone, neither product is first in line. A cross-linked hyaluronic acid comes before both.

The US FDA guidance on Minimal Manipulation and Homologous Use (July 2020), example 10-4(b), describes removing the epidermis and grinding the dermis into particles as generally more than minimally manipulated, because it alters the characteristics of skin relevant to its use as a protective covering. 21 CFR 1271.10(a)(3) further limits combination with another substance — water, crystalloids and sterilising, preserving or storage agents are permitted, and hyaluronic acid is not among them. A particulated dermis product combined with hyaluronic acid therefore would not meet the 361 HCT/P criteria in the United States.

Worth noting alongside it: the 20-subject paper describes this material as a “minimally manipulated, human-derived biomaterial,” which sits directly against FDA example 10-4(b). The two sources should not be read as agreeing.

This says nothing about whether the product is good. It says the regulatory systems differ. But if you have been told a product is “used in the US too,” it is worth checking.

Which procedure fits is decided by the state of your skin today, not by the product. In consultation we look first at what has been lost and what remains, before any product name.

• Juvelook — PDLLA with hyaluronic acid
• RE2O — hADM
• RE2O and Rejuran, what separates them
• Seven collagen boosters compared

Written and reviewed by Lee Chi-Hak, MD, director of Miso Clinic in Daegu. Where a study is cited, its size and limits are cited with it; where we could not find a source, we say so. The same standard is applied to the products this clinic uses. Individual assessment requires examination, and this page does not substitute for it.